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Background: The mammalian target of rapamycin (mTOR) is a kinase involved in a variety of physiological and
pathological functions. However, the exact role of mTOR in excitotoxicity is poorly understood. Here, we investigated
the effects of mTOR inhibition with rapamycin against neurodegeneration, and motor impairment, as well as
inflammatory profile caused by an excitotoxic stimulus.
Methods: A single and unilateral striatal injection of quinolinic acid (QA) was used to induce excitotoxicity in
mice. Rapamycin (250 nL of 0.2, 2, or 20 μM; intrastriatal route) was administered 15 min before QA injection.
Forty-eight hours after QA administration, rotarod test was performed to evaluate motor coordination and
balance. Fluoro-Jade C, Iba-1, and GFAP staining were used to evaluate neuronal cell death, microglia morphology, and
astrocytes density, respectively, at this time point. Levels of cytokines and neurotrophic factors were measured by ELISA
and Cytometric Bead Array 8 h after QA injection. Striatal synaptosomes were used to evaluate the release of glutamate.
Results: We first demonstrated that rapamycin prevented the motor impairment induced by QA. Moreover, mTOR
inhibition also reduced the neurodegeneration and the production of interleukin (IL)-1β, IL-6, and tumor necrosis factor
(TNF)-α induced by excitotoxic stimulus. The lowest dose of rapamycin also increased the production of IL-10 and
prevented the reduction of astrocyte density induced by QA. By using an in vitro approach, we demonstrated that
rapamycin differently alters the release of glutamate from striatal synaptosomes induced by QA, reducing or enhancing
the release of this neurotransmitter at low or high concentrations, respectively.
Conclusion: Taken together, these data demonstrated a protective effect of rapamycin against an excitotoxic stimulus.
Therefore, this study provides new evidence of the detrimental role of mTOR in neurodegeneration, which might
represent an important target for the treatment of neurodegenerative diseases.
Keywords: Neurodegeneration, mTOR, Rapamycin, Quinolinic acid, Inflammation, Glutamate, Neurotrophic factorsBackground
Huntington’s disease (HD) is an autosomal dominant inher-
ited neurodegenerative disease, which manifests with motor
dysfunction, psychiatric symptoms, and cognitive decline.
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striatum of rodents is used as a neurotoxic animal model of
HD since it mimics the deficits seen in early stages of neu-
rodegeneration in this disease, leading to the loss medium
spiny projection neurons (MSNs) in the striatum [3–5].
QA is an agonist of the NMDA receptor [6]. High
concentrations of this compound are shown to increase
glutamate release and also the influx of calcium ions
leading to the excitotoxic process. Besides, it inhibits the
glutamate reuptake by astrocytes [6–10]. In addition to
excitotoxicity, QA also induces mitochondrial dysfunc-
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of rapamycin (PI3K/mTOR) pathway is involved in many
physiological and pathological processes. The activation
of this pathway by different stimuli induces the phos-
phorylation of phosphatidylinositol 4,5-bisphosphate
(PIP2) by PI3K enzyme to generate phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 facilitates the phosphor-
ylation of Akt by the phosphoinositide-dependent
kinase-1 (PDK-1) and mTOR complex 2 (mTORC2).
The phosphorylation of the Akt leads to further catalytic
activity changes of downstream targets, such as
forkhead-related transcription factor 1, Bad, glycogen
synthase kinase-3 (GSK-3), and mTOR complex 1
(mTORC1) [12, 13].
mTOR is a serine/threonine protein kinase that partic-
ipates in the regulation of cell growth and proliferation,
as well as in several intracellular processes, such as
mRNA transcription and translation, autophagy and
cytoskeletal organization. mTOR is involved in the
pathophysiology of different conditions, being, for ex-
ample, a potential pharmacological target for the treat-
ment of cancer and diabetes [14]. mTOR forms two
distinct functional complexes termed mTOR complexes
1 (mTORC1) and 2 (mTORC2). The mTORC1 is the
primary target of inhibition by the drug rapamycin, but
higher concentration of rapamycin or chronic treatment
can also interfere on mTORC2 regulation [15]. In this
context, the implication of mTOR in neuropathological
conditions has being suggested. In fly and mouse genetic
models of HD, inhibition of mTOR by rapamycin in-
duced autophagy and reduced toxicity of polygluta-
mine expansions [16]. Administration of rapamycin
reduced the number of activated microglia/macro-
phages and increased the number of surviving neurons
at the cortical region near the site of the lesion in an
animal model of head injury [17]. Moreover, this kin-
ase regulates the expression of type 1 glutamate trans-
porter in astrocytes [18].
The effects of mTOR inhibition on the inflammatory
process are not clear. mTOR inhibition in primary
microglial cultures increased the production of cyclooxy-
genase (COX)-2 and microsomal prostaglandin E
synthase-1 (mPGES-1) after stimulation with LPS and
poly(I:C) [19, 20]. In peripheral blood mononuclear cells,
rapamycin increased the release of interleukin (IL)-12, a
pro-inflammatory cytokine, and reduced IL-10 after LPS
stimulation [21]. On the other hand, in microglia cul-
tures stimulated with LPS, rapamycin reduced the ex-
pression of nitric oxide synthase (NOS) and COX-2 [22,
23]. Thus, this kinase could be involved in the excito-
toxicity and neuroinflammation observed in neurode-
generative diseases.
Although few studies have evaluated the role of mTOR
in traumatic brain injury and genetic models ofneurodegeneration, its role in the pathological processes
associated with excitotoxic injury, an event present in
neurodegenerative diseases, is poorly understood. There-
fore, in the present study, we investigated the effect of
mTOR inhibition on neurodegeneration and neuroin-
flammation induced by intrastriatal injection of QA.
Methods
Animals
Male C57Bl/6 mice (10–12 weeks), bred in the vivarium
of the Federal University of Minas Gerais, were used.
Animals were kept under standard laboratory condi-
tions, maintained on 12-h light/dark cycle with
temperature of 24 °C and free access to water and food.
Mice were acclimatized in the experimental room
30 min before the test. All the experiments were per-
formed between 8 a.m. and 5 p.m. All the experiments
were approved by the Ethics Committee on Animal Ex-
perimentation (CEUA) of the Federal University of
Minas Gerais (protocol number 327/2012).
Drugs
Rapamycin (LC Laboratories, Woburn, MA, USA), a
mTOR inhibitor, was first dissolved in DMSO 100%
(Sigma-Aldrich, St Louis, MO, USA) to create a 10 mM
stock solution. Thereafter, the drug was diluted with sa-
line to reach the concentrations of 0.2, 2, or 20 μM.
Two hundred fifty nanoliters of rapamycin were admin-
istered into the right striatum. Therefore, the total
amount of rapamycin injected were doses of 5 × 10−5,
5 × 10−4, or 5 × 10−3 nmol. The vehicle had the same
concentration of DMSO that the rapamycin solution.
Quinolinic acid (Sigma-Aldrich, St Louis, MO, USA)
was dissolved in phosphate-buffered saline (PBS, pH 7.0)
and administered unilaterally in the right striatum
(250 nL of a 0.8 M solution). Thus, the total amount of
QA injected was 200 nmol.
Intrastriatal administration of rapamycin and QA
In order to avoid peripheral pharmacological responses
and to investigate the local actions of mTOR inhibition,
we injected rapamycin directly in the striatum. Animals
were anesthetized with a solution of ketamine and xyla-
zine (80 and 8 mg/kg, respectively) to implant the can-
nula guide unilaterally into the right striatum. The
following coordinates were used for the administration
of rapamycin and QA in the striatum: anteroposterior
+0.6 mm, mediolateral −2.1 mm, and dorsoventral
−2.2 mm from the bregma based on the atlas by Paxinos
and Watson [24] (Additional file 1: Figure S1). After
7 days, rapamycin and QA were injected using a 30-
gauge stainless steel needle attached to a Hamilton syr-
inge. Rapamycin or vehicle (5% DMSO in saline) was
injected at 0.08 μL/min, and the injection needle was left
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avoid the reflux of the solution. After 15 min, QA or
PBS were administered over a period of 3 min, and the
injection needle was left in place for another 1 min to
allow diffusion and to avoid the reflux of the solution.
Animals were divided into six groups: vehicle + PBS;
vehicle + QA; rapamycin 0.2 μM + PBS; rapamycin
0.2 μM + QA, rapamycin 2 μM + QA, and rapamycin
20 μM + QA. The behavioral and biochemical assess-
ments were performed as shown in Additional file 1:
Figure S1.
Body weight
Body weight of the animals was evaluated before the ad-
ministration of the drugs (QA and/or rapamycin) and on
the last day of the study.
Rotarod activity
Motor coordination and balance were assessed using
rotarod (Insight®, São Paulo, Brazil). Before the surgery
for implantation of the guide cannula, all the animals
were given a prior training session on the rotarod appar-
atus, which consisted of three consecutive days at low
rotational speeds (14, 17, 2,0 and 24 rpm) for 3 min
each. Seven days after the surgery, mice were placed on
the rod starting at 14 rpm and accelerating to 37 rpm
within 5 min [25]. Three trials were conducted, and the
time that the animals stayed on the rod before falling off
was measured and considered the baseline performance.
After 2 days of QA or PBS administration, the latency
for the animals to fall off was recorded again for each
animal.
Brain extraction and sectioning
Two days after the administration of QA or PBS, mice
were anesthetized with a solution of ketamine and xyla-
zine (80 and 8 mg/kg, respectively), and perfused with
PBS 1× followed by 4% paraformaldehyde (PFA). The
brains were harvested, and then fixed with the same so-
lution for 24 h at 4 °C, and cryoprotected for additional
2 days by immersion in 30% sucrose at 4 °C. The stri-
atum was sectioned at 30 μm with a cryostat (Leica Bio-
system, USA) at −20 °C. A series of four coronal
sections of the central striatum was mounted for im-
munofluorescence analysis and stained with Fluoro-Jade
C (FJC), ionized calcium-binding adapter molecule 1
(Iba-1), and glial fibrillary acidic protein (GFAP).
Assessment of degenerating neurons
FJC analysis was used to quantify the number of degen-
erating neurons in the striatum. Brain sections were
mounted on gelatin-coated slides, air-dried, and sub-
jected to FJC staining. Slides were first immersed in a
solution containing 1% NaOH in 80% ethanol for 5 min.They were rinsed for 2 min in 70% ethanol and for
2 min in distilled water, and then incubated in 0.06% po-
tassium permanganate solution for 20 min. Thereafter,
the slides were rinsed with water for 2 min and incu-
bated in 0.0001% FJC solution for 20 min. The 0.0001%
FJC solution was prepared by first making a 0.01% stock
solution of FJC dye in distilled water and then adding
1 mL of the stock solution to 99 mL of 0.1% acetic acid.
Slides were washed two times each for 1 min and then
air-dried on a slide warmer at 37 °C. After 10 min, sec-
tions were washed, dried, cleared in xylene, and cover
slipped in DPX mounting media. Sections were imaged
in a Zeiss fluorescent microscope (Zeiss, Oberkochen,
Germany) using a 488 nm excitation. Quantification of
fluorescence intensity was done using ImageJ software.
The number of fluorescent points in each picture, indi-
cating the dead neurons, was counted by an investigator
blinded to the experimental groups.
Assessment of glial cells
Evaluation of glial cells, such as microglia and astrocytes,
was determined by performing Iba-1 and GFAP im-
munofluorescence, respectively. In brief, central striatum
sections (30 μm) were first blocked with 4% bovine
serum albumin (BSA) containing 0.05% Triton in Tris-
buffered saline (TBS) and then incubated with the indi-
cated primary antibodies (1:400 with anti-Iba1 from
WAKO or 1:1000 with GFAP from Santa Cruz Biotech-
nology) overnight at 4 °C. Slides were then incubated
with secondary antibody for 1 h at room temperature.
Rabbit highly cross-adsorbed AlexaFluor 594 or Alexa-
Fluor 488 secondary antibody (Invitrogen, Carlsbad, CA,
USA) was used to detect Iba-1 or GFAP, respectively.
Sections were imaged in a Zeiss fluorescent microscope
(Zeiss, Oberkochen, Germany) and quantified with Ima-
geJ software. The cell area of microglia and astrocyte
density were estimated using ImageJ software, and the
results presented as cell area divided by the number of
cells for microglia and for astrocytes, intensity of the sig-
nal divided by the area.
Quantification of neurotrophic factors and cytokines in
striatum
Eight hours after the administration of QA or PBS, the
right and left striatum were dissected and kept at −80 °C
until tested. Samples were homogenized in 200 μL of
protease inhibitor solution [NaCl 0,4 M; Tween 20
(Synth) 0.05%; bovine serum albumin (BSA) (Inlab Con-
fiança) 0.5%; phenylmethylsulfonylfluoride (Calbiochem)
0.1 mM; benzethonium chloride (Vetec) 0.1 mM; EDTA
10 mM; 20 UI de aprotinin (Sigma), diluted in PBS]. Ho-
mogenates were centrifuged at 4 °C at 10,000 rpm, ali-
quoted, and stored at −80 °C until analysis. Brain-
derived neurotrophic factor (BDNF), nerve growth factor
Fig. 1 Effect of rapamycin on rotarod activity 2 days after QA
administration (n = 8–15 animals/group). Rapamycin was injected
15 min before QA injection into the striatum and after 2 days,
rotarod performance was evaluated. Results are expressed as mean
± SEM (% of basal performance). ***p < 0.001 and **p < 0.01 as
compared to vehicle + PBS. #p < 0.05 as compared to vehicle + QA.
§§p < 0.01 as compared to Rapa 0.2 + QA (two-way ANOVA followed
by Bonferroni test)
Saliba et al. Journal of Neuroinflammation  (2017) 14:25 Page 4 of 12(NGF), and interleukin (IL)1β protein levels were
assessed using ELISA kits (R&D Systems, Abingdon,
UK) according to the manufacturer protocol. IL-2, IL-4,
IL-6, interferon (IFN) γ, tumor necrosis factor alpha
(TNF-α), IL-10, and IL-17A were assessed using Th1/
Th2 kit (BD Pharmigen, CA, USA) by Cytometric Bead
Array (CBA) method according to the protocol of the
manufacturer. The results of the ELISA and CBA were
expressed as pg/mg of total protein.
Preparation of synaptosomes
Male C57Bl/6 mice (10–12 weeks) were decapitated, and
the striatum was removed and homogenized in 1:10 (w/
v) 0.32 M sucrose containing 0.25 mM dithiothreitol
and 1 mM EDTA. Homogenates were then submitted to
low-speed centrifugation (1000×g/10 min), and the iso-
lated nerve terminals (synaptosomes) were purified from
the supernatant by discontinuous Percoll density gradi-
ent centrifugation [26]. The isolated synaptosomes were
resuspended in 400 μL Krebs-Ringer-HEPES (KRH) so-
lution (124 mM NaCl, 4 mM KCl, 1.2 mM MgSO4,
10 mM glucose, 25 mM HEPES, pH 7.4) without
addition of CaCl2 and were kept on ice until use for the
quantification of glutamate release.
Measurement of continuous glutamate release
Glutamate release was measured by continuous fluoro-
metric assay as described by Nicholls et al. [27]. Briefly,
300 μL of synaptosomes with CaCl2 (1 mM), NADP
+
(1 mM), and KRH medium was added in wells of the
ELISA plate. First, to evaluate the effect of QA on
glutamate release, glutamate dehydrogenase (GDH)
(35 units/well) was mixed with the striatal synaptosomes
followed by the addition of QA (0.1, 0.5, 5, and 10 mM)
or PBS or KCl 33 mM. To study the effect of rapamycin
on glutamate release, synaptosomes were previously in-
cubated with rapamycin (10−4, 10−3, 0.05, or 0.25 nM)
for 15 min and GDH (35 units/well) were added to syn-
aptosomes. Thereafter, QA 5 mM or PBS or KCl 33 mM
were added. The glutamate measurement was performed
by the increase in fluorescence due to the production of
NADPH+ in the presence of glutamate dehydrogenase
and NADP+. Calibration curves were prepared in parallel
by adding known amounts of glutamate to the reaction
medium. Fluorescence emission was recorded using a
fluorometer (Biotek Synergy 2) at 450 nm, and the exci-
tation wavelength was set at 360 nm. Results are
expressed as percentage of the QA group (mean ± SEM).
Statistical analysis
Data are presented as mean ± SEM. The data was ana-
lyzed using one-way analysis of variance (ANOVA)
followed by Newman-Keuls post-test and two-way
ANOVA followed by Bonferroni post-tests asappropriate. The level of statistical significance was set
at a p value less than 0.05. Graph Pad Prism (Graph Pad
Software, San Diego, CA) was used for performing all
statistical analysis.
Results
Rapamycin prevents motor impairment induced by QA
QA intrastriatal injection leads to a significant decrease
in motor coordination as observed in HD animal models
[28]. To test whether rapamycin prevents motor dys-
function induced by QA, animals were evaluated by
rotarod activity. Intrastriatal QA administration signifi-
cantly reduced rotarod performance (% of fall off time)
as compared to control animals (Fig. 1). The lower dose
of rapamycin (0.2 μM/250 nl) prevented the motor im-
pairment induced by QA. This same dose of rapamycin
did not alter the motor performance of the animals
treated with PBS. The other concentrations of rapamycin
did not alter the performance of the animals in the
rotarod in comparison with the QA-injected group
(Fig. 1). None of the treatments produced any significant
change in body weight (Additional file 2: Figure S2).
Rapamycin decreases neurodegeneration of striatal
neurons induced by QA
Neostriatal atrophy is the morphologic hallmark of HD
[29]. In order to investigate whether the effect of rapa-
mycin on the motor impairment is due to a reduced
neuronal cell death, we performed Fluoro-Jade C stain-
ing. QA significantly increased the neuronal cell death in
the striatum as compared with negative control (Fig. 2a, b).
It is possible to observe a change in tissue morphology in
the ipsilateral striatum in all groups with QA administra-
tion, suggesting tissue degeneration (Fig. 2b-e). Importantly,
Fig. 2 Effect of rapamycin on neurodegeneration 2 days after QA administration (n = 5–7 animals/group). Rapamycin was injected 15 min before
QA injection into the striatum and after 2 days, and dead neurons were evaluated. a–e Representative FJC of the right striatum in 10×. f A graph
of the FJC data of the right striatum. Results are expressed as mean ± SEM. ***p < 0.001 as compared to vehicle + PBS. ##p < 0.001 as compared to
vehicle + QA. §§p < 0.01 as compared to Rapa 0.2 + PBS (one-way ANOVA followed by Newman-Keuls test)
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cell death induced by QA (Fig. 2c and f). Although a trend
towards a decrease in QA-induced damage is also observed
with the higher dose of rapamycin, no statistical difference
was observed (Fig. 2e and f).
Rapamycin alters glutamate release induced by QA in
synaptosomes
In order to investigate whether rapamycin would modu-
late neurotransmitter release, an effect that could
contribute to the neuroprotective effect of rapamycin,
we evaluated its effect on glutamate release insynaptosomes. We first demonstrated that QA increases
the release of glutamate in synaptosomes prepared from
mice striatum (Fig. 3a). Rapamycin reduced QA-induced
glutamate release from synaptosomes at the lower con-
centrations (0.0001–0.001 nM) and enhanced the release
of this neurotransmitter at higher concentrations
(>0.05 nM, Fig. 3b).
Rapamycin does not alter neurotrophic factors
production in the striatum after QA administration
We next evaluated whether rapamycin would alter the
production of neurotrophic factors shortly after the
Fig. 3 Effect of different concentrations of QA and rapamycin on
the glutamate release in striatal synaptosomes. a Synaptosomes
were incubated with different concentration of QA (0.1, 0.5, 5, and
10 mM) (n = 2–3). b Previously, synaptosomes were incubated with
rapamycin (10−4, 10−3, 0.05, or 0.25 nM) for 15 min, and after, QA
5 mM were added. The glutamate release was evaluated by continuous
fluorometric assay. Results are expressed as mean ± SEM (n = 3–10
independent experiments/group). **p < 0.05, ***p < 0.01 as compared
with KCl 33 mM. ###p < 0.001, ##p < 0.01, and #p < 0.05 as compared
with QA 5 mM (one-way ANOVA followed by Newman-Keuls test)
Fig. 4 Effect of rapamycin on the levels of neurotrophic factors in
the striatum after 8 h of QA administration. Rapamycin was injected
15 min before QA injection into the striatum, and the quantification
of BDNF (n = 6–7 animals/group) (a) and NGF (n = 5–7 animals/
group) (b) was determined after 8 h of the QA injection using ELISA.
Results are expressed as mean ± SEM. There are no statistically
significant differences among treatment groups (one-way ANOVA
followed by Newman-Keuls test)
Saliba et al. Journal of Neuroinflammation  (2017) 14:25 Page 6 of 12injection of the excitotoxic stimulus, which could modify
the neuronal cell death 2 days after injection. QA did
not statistically alter the production of BDNF and NGF
8 h after the injection, although a trend towards reduc-
tion was observed. Moreover, rapamycin also did not
affect the levels of these neurotrophins at this time point
(pBDNF = 0.1688 and pNGF = 0.4336) (Fig. 4).
Rapamycin alters cytokine production in the striatum
after QA administration
In order to investigate whether rapamycin could alter
the production of inflammatory mediators, which could
be a consequence of the neurodegenerative process and
also contribute to neuronal damage, we investigated the
production of cytokines 8 h after the stimulus. Quantifi-
cation of cytokines was performed in the ipsilateral
hemisphere. As shown in Fig. 5a–c, IL-1β, IL-6, and
TNFα were increased by QA injection. All theconcentrations of rapamycin reduced these cytokines in-
duced by QA (Fig. 5a–c). On the other hand, although a
trend towards increase in IL-10 was induced by QA
(Fig. 5d), no statistical difference was observed. However,
the lower dose of rapamycin (0.2 μM/250 nl) increased
the levels of this cytokine in comparison with QA group
(Fig. 5d).
QA also reduced the levels of IFNγ (Fig. 5e), which
was not significantly altered by rapamycin treatment.
None of the other cytokines (i.e., IL-2, IL-4, IL-17A)
were altered by the treatment with QA and/or rapamy-
cin at this time point (Fig. 5f–h).
Rapamycin does not alter the morphology of microglia in
the striatum of QA-treated animals
We next evaluated whether the alteration in production
of inflammatory mediators would be accompanied by
changes in microglial morphology. We evaluated micro-
glia at 48 h after the stimulus because the activation of
these cells would be present due to severe neurodegen-
erative process at this time point. Microglia activation,
Fig. 5 Effect of rapamycin on IL-1β (a), IL-6 (b), TNFα (c), IL-10 (d), IFN-γ (e), IL-2 (f), IL-4 (g), and IL-17A (h) levels in the striatum after 8 h of QA
administration (n = 5–7 animals/group). Results are expressed as mean ± SEM. ***p < 0.001, **p < 0.01, and *p < 0.05 as compared to vehicle + PBS.
###p < 0.001, ##p < 0.01, and #p < 0.05 as compared to vehicle + QA (one-way ANOVA followed by Newman-Keuls test)
Saliba et al. Journal of Neuroinflammation  (2017) 14:25 Page 7 of 12as revealed by their retraction of their projections and
enlarged cell bodies, was increased in the QA group
(Fig. 6b). We performed an analysis to investigate
whether the cell size would be affected by rapamycin.
For this, we determined the area of the cells and divided
this area by the number of cells. We observed that the
cell size increased with QA injection, but no differencewas observed with the groups treated with rapamycin
(Fig. 6c-f).
Rapamycin prevented the reduction in astrocyte density
in the striatum of QA-treated animals
Astrocytes possess various physiological functions and
also contribute to inflammation associated with
Fig. 6 Effect of rapamycin on microglia activation after 2 days of QA administration (n = 3–4 animals/group). Rapamycin was injected 15 min
before QA injection into the striatum, and after 2 days, Iba-1 staining was performed. a–e Representative images of the staining with anti-Iba-1
antibody in the right striatum at 20× (ipsilateral). f Quantitative analysis of the cell area divided by the number of the cells. Results are expressed
as mean ± SEM. *p < 0.05 as compared with vehicle + PBS (one-way ANOVA followed by Newman-Keuls test)
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these cells were affected by QA and the effect of rapa-
mycin on it. As demonstrated in Fig. 7, QA reduced the
astrocyte density, which was prevented by the treatment
with the lower dose of rapamycin (0.2 μM/250 nl), but
not by the others.
Discussion
In the present study, we evaluated the effect of rapamy-
cin in the excitotoxicity induced by intrastriatal injection
of QA. We demonstrated that this drug prevented the
motor impairment and the reduction of astrocyte dens-
ity, reduced neuronal cell death, and attenuated theinflammatory process associated with neurodegeneration
induced by QA.
We first demonstrated that the lower, but not the
higher doses of rapamycin, prevented the motor impair-
ment induced by QA. Although it is difficult to explain
this effect with the results of the present work, drugs
may have variable effects depending on the concentra-
tion. Some studies have shown that higher concentra-
tions of rapamycin inhibit not only mTORC1 but also
mTORC2, as well as influence calcium signaling [15,
30]. Low concentrations of rapamycin can improve
learning and memory [31, 32]. However, high concentra-
tions of rapamycin completely inhibit mTOR, affect
Fig. 7 Effect of rapamycin on astrocyte density after 2 days of QA administration (n = 3–4 animals/group). Rapamycin was injected 15 min before
QA injection into the striatum, and after 2 days, GFAP staining was performed. a–e Representative images of the staining with GFAP antibody in
the right striatum at 20× (ipsilateral). f Quantitative analysis of the density divided by the area. Results are expressed as mean ± SEM. *p < 0.05 as
compared with vehicle + PBS and ##p < 0.01 as compared to vehicle + QA (one-way ANOVA, Newman-Keuls test)
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cause amnesia [32, 33].
In order to investigate whether the effect of rapamy-
cin on the motor impairment was due to a reduced
neuronal cell death, we performed Fluoro-Jade C ana-
lysis. We showed that the lower dose of rapamycin re-
duced the neuronal death induced by the excitotoxic
stimulus. This neuroprotection induced by rapamycin
could be due to reduced neuronal firing. Indeed, rapa-
mycin has been shown to reduce excitatory postsynap-
tic current (EPSC) in glutamatergic neurons [34].
Moreover, rapamycin decreased the neurotoxic effect
of glutamate insult on hippocampal neuronal cultures
through a mechanism involving increased autophagy[35], and also, in a rat model of NMDA-induced ret-
inal injury [36, 37] and kainate rat model [38], rapa-
mycin has been shown to confer neuroprotection
against neurotoxicity. This neuroprotective effect of
rapamycin have also been demonstrated in other neu-
rodegenerative models, such as in traumatic brain in-
jury model [39, 40], mouse model of early-stage
Alzheimer’s disease (AD)-type tauopathy [41] and
spinal cord injury [42]. On the other hand, our group
has recently demonstrated that rapamycin does not
alter the neuronal cell death induced by intrahippo-
campal injection of amyloid beta [43]. The effects of
rapamycin seem to be dependent on the type or period
of stimuli and dose [44].
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release of glutamate in rat synaptosomes. In the present
study, we demonstrated that QA increased the release of
glutamate from mice striatal synaptosomes. Interestingly,
rapamycin reduced QA-induced glutamate release at low
concentrations and produced the opposite effect at
higher concentrations. Although it might be speculative
to extrapolate the effect of specific concentrations used
in vitro to doses used in in vivo experiments, these re-
sults suggest that low concentrations of rapamycin, by
decreasing the release of glutamate, would lead to a re-
duced neuronal death, consequently avoiding the motor
impairment induced by QA. In accordance with our
study, hyperactivation of mTOR increased the evoked
synaptic responses in glutamatergic neurons, and rapa-
mycin reduced this response [34]. Therefore, although
the main role of mTOR is regarded as pro-survival, in-
hibition of this kinase might be neuroprotective in exci-
totoxic conditions.
Neurotrophic factors such as BDNF and NGF promote
neuronal survival as well as cell proliferation and differ-
entiation of neurons [45]. In the striatum, BDNF is im-
portant for neuronal activity and survival [46]. Mishra
and Kumar [47] have shown that a single intrastriatal bi-
lateral QA administration in Wistar rats decreased
BDNF after 21 days. In the current study, no change was
observed in the levels of BDNF and NGF after injection
of QA. The short time point, i.e., 8 h after QA, at which
we measured these neurotrophins could possibly explain
this discrepancy between the studies. Furthermore, it is
also possible that these neurotrophic factors may not
contribute to the neuroprotective effect of rapamycin in
this model.
The production of cytokines usually occurs immedi-
ately after excitotoxic events [48]. Schiefer et al. [48]
have shown that the unilateral administration of
240 nmol of QA in the striatum of Wistar rats increased
IL-6 levels after 3 h, and the maximal levels were ob-
served at 6 h, followed by a reduction at 24 h. Therefore,
we used 8 h after stimulation with QA to evaluate the
levels of the cytokines. We observed that QA-injected
mice increased pro-inflammatory cytokines when com-
pared with all rapamycin-treated groups and PBS-
injected controls. In our model, all concentrations of
rapamycin reduced the content of IL-1β, IL-6, and TNFα
induced by QA. Indeed, other studies have shown that
rapamycin inhibits the production of IL-1β and IL-6 in
LPS-stimulated microglia [49] and reduces and delays
the LPS increase in IL-1β and TNF-α in a rat model of
absence epilepsy [50]. On the other hand, we have
shown that only the low dose of rapamycin enhanced
IL-10, an anti-inflammatory cytokine that has been dem-
onstrated to exhibit neuroprotective effects [51, 52]. Al-
though the most important source of cytokines ismicroglia, it has been shown that QA also induced the
production of IL-1β by human astrocytes [53]. Further-
more, rapamycin reduced the release of IL-1β and TNF
in astrocytes exposed to ischemia [54]. Thus, it is pos-
sible that, in our model, rapamycin reduced the produc-
tion of cytokines induced by QA also in astrocytes. As
demonstrated previously, in addition to excitotoxicity,
neuronal cell death can also occur due to an enhanced
inflammatory process [55]. However, in the current
study, a sole reduction in the production of pro-
inflammatory mediators does not seem to influence the
neuronal death as all doses of rapamycin reduced the
levels of IL-1β, IL-6, and TNF, while only the lower con-
centration of the drug revealed a neuroprotective effect.
Microglia, an immune cell of the central nervous sys-
tem, plays a pivotal role in neurodegenerative processes
and can modulate the production of inflammatory medi-
ators. We thus evaluated whether this compound alters
microglia activation in QA-injected mice immediately
after the evaluation of the motor performance. We ob-
served that microglia from QA-injected mice were more
activated than the PBS-injected controls, as demon-
strated by their enlarged cell bodies and retraction of the
projections. However, rapamycin did not change the
morphology of microglia. This lack of effect might be
because we used just one administration, and the
morphology of the cells was evaluated only at 2 days
after the QA stimulus. Finally, this result, together with
the data of the cytokines, suggests that microglia activa-
tion and neuroinflammation does not seem to mediate
the neuroprotective effects of rapamycin in this model.
Other important cells from the central nervous system
that are also involved in neurodegenerative processes are
the astrocytes [56]. In the present study, we observed a
reduced density of astrocytes in the group treated with
QA. Considering the important physiological role of
these immune cells in glutamate homeostasis, a reduc-
tion in their number would lead to a lower reuptake of
this neurotransmitter. Since QA also enhances the re-
lease of glutamate, both effects could enhance the exci-
totoxic process. Therefore, one could speculate that a
possible mechanism by which the lower dose of rapamy-
cin partially prevents neurodegeneration and motor im-
pairment would be by avoiding the reduction in
astrocyte density induced by QA, which could contrib-
ute to maintain their physiological functions in the
striatum.
Conclusions
In conclusion, we demonstrated that mTOR inhibition
with rapamycin reduced the motor impairment and neu-
rodegeneration in an animal model of excitotoxicity,
providing evidence of the involvement of mTOR in exci-
totoxic events. Our data suggest that the neuroprotective
Saliba et al. Journal of Neuroinflammation  (2017) 14:25 Page 11 of 12effects of rapamycin against QA-induced excitotoxicity
might be due to different mechanisms including modu-
lation of glutamate release and maintenance of the via-
bility of the astrocytes. However, further studies are
necessary to determine the precise mechanism of neuro-
protection induced by rapamycin in excitotoxicity.
Finally, considering that higher concentrations of rapa-
mycin enhanced the release of glutamate by synapto-
somes, a possible neurotoxic effect of the drug should
also be investigated in other models.
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